Skip to content

ASHCOM Shoulder System and Its Related Instruments

ASHCOM Shoulder System and Its Related Instruments - A Multicenter, Prospective, Non-Controlled Post Market Clinical Follow-up Study

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04258605
Enrollment
24
Registered
2020-02-06
Start date
2019-12-10
Completion date
2024-08-13
Last updated
2025-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthropathy; Traumatic, Arthroplasty Complications, Rotator Cuff Injuries, Shoulder Pain

Brief summary

The objectives of this study are to confirm safety, performance and clinical benefits of the ASHCOM Shoulder System and its related instruments by analysis of standard scoring systems, radiographs and adverse event records.

Detailed description

This study is a multicenter, prospective, non-controlled Post-Market Clinical Follow-up study involving orthopaedic surgeons skilled in reverse shoulder arthroplasty procedures. A minimum of three study centers will be involved. A total number of 97 implants will be included into the study. The primary endpoint is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. The secondary endpoint is defined by the performance and clinical benefits of the ASHCOM Shoulder System at 5 years, which is assessed by the Constant and Murley score. Assessments of the overall pain, functional performance, survival, quality of life and radiographic parameters of all enrolled study subjects will be evaluated in addition.

Interventions

DEVICEASHCOM Shoulder System

Reverse Shoulder Arthroplasty

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient is capable of understanding the doctor's explanations, following his instructions and is able to participate in the follow-up program. * Patient has given written consent to take part in the study by signing the Patient Consent Form. * Patient is 18-80 years of age, inclusive. * Patient is skeletally mature. * Patient requires a primary, fracture or revision reverse total shoulder replacement for the relief of pain and has significant disability due to gross rotator cuff deficiency. * Patient's joint is anatomically and structurally suited to receive the selected implants. * Patient has a functional deltoid muscle.

Exclusion criteria

* Patient is unwilling or unable to give consent or to comply with the follow-up program. * Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them. * Patient is known to be pregnant or breastfeeding. * Patient is a vulnerable subject. * Patient meets at least one of the contraindications: * Signs of infection * Significant injury to the upper brachial plexus * Non-functional deltoid muscle * Insufficient quality and/or quantity of glenoid or humeral bone * Any neuromuscular or vascular disease compromising the affected limb that would endanger the success of the intervention

Design outcomes

Primary

MeasureTime frameDescription
Survival of Implant System (Kaplan Meier)3 yearsThe primary endpoint is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method. Due to early study termination, the survival of the implant was analyzed at 3 years.

Secondary

MeasureTime frameDescription
The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)Pre-operative (baseline), 1 year, 2 years post-operativeThe secondary endpoint of this study is defined by the performance and clinical benefits of the ASHCOM Shoulder System at 5 years, which is assessed by the Constant and Murley score. Due to early study termination, the Constant and Murley Score was assessed at 2 years. The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points. The minimum score is 0 points (worst outcome), the maximum score possible is 100 points (best outcome).
Oxford Shoulder Score (OSS)Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operativeThe Oxford Shoulder Score (OSS) is a patient-reported outcome questionnaire that was developed to specifically assess the patient's perspective of outcome following total shoulder arthroplasty. The OSS consists of twelve questions covering function and pain associated with the shoulder. To calculate the total score, each question is scored from 0 (worst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible and a minimum of 0, representing the worst possible. The outcome score can be categorized as: Satisfactory Joint Function: 40 - 48, Moderate-Mild Arthritis: 30 - 39, Moderate-Severe Arthritis: 20 - 29, Severe Arthritis: 0 - 19.
EQ-5D-5L ScorePre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operativeThe EQ-5D-5L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes 5 questions referring to mobility, self-care, daily activities, pain/discomfort and anxiety/depression. Each question can be answered in five ways, indicating no, slight, moderate, severe problems or inability to complete the task. In the derived EQ-5D-5L score, the highest score is 1 and the lowest score is -0.573. It included the Health State, which is a self-reported assessment about the patient's health on that day at a VAS from 0 to 100 with 100 being the best health one can imagine and 0 the worst.
Subjective Shoulder Value (SSV)Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operativeThe Subjective Shoulder Value (SSV) is a single point, subjective estimate of a patient's condition. The patient is asked to rate the functionality of their operated shoulder on a scale of 0% - 100% of normal.
Radiographic Parameters2 years post-operativeRadiographic parameters: X-rays have been evaluated for radiolucency, osteolysis, atrophy, hypertrophy, osteophytes (glenoid), component migration (humeral stem subsidence / glenoid component migration), heterotopic ossification and scapular notching

Countries

Italy

Participant flow

Participants by arm

ArmCount
ASHCOM Shoulder System Subjects - Uncemented Humeral Stem
Subjects implanted with the ASHCOM Shoulder System and an uncemented humeral stem ASHCOM Shoulder System: Reverse Shoulder Arthroplasty
22
ASHCOM Shoulder System Subjects - Fracture Humeral Stem
Subjects implanted with the ASHCOM Shoulder System and a fracture humeral stem ASHCOM Shoulder System: Reverse Shoulder Arthroplasty
2
Total24

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath10
Overall StudyEarly study termination212

Baseline characteristics

CharacteristicASHCOM Shoulder System Subjects - Uncemented Humeral StemASHCOM Shoulder System Subjects - Fracture Humeral StemTotal
Age, Continuous70.14 years
STANDARD_DEVIATION 6.14
72.5 years
STANDARD_DEVIATION 3.54
70.33 years
STANDARD_DEVIATION 5.95
Preop BMI26.34 kg/m^2
STANDARD_DEVIATION 2.46
22.2 kg/m^2
STANDARD_DEVIATION 1.13
25.99 kg/m^2
STANDARD_DEVIATION 2.64
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
Italy
22 participants2 participants24 participants
Sex: Female, Male
Female
10 Participants2 Participants12 Participants
Sex: Female, Male
Male
12 Participants0 Participants12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 220 / 2
other
Total, other adverse events
0 / 220 / 2
serious
Total, serious adverse events
1 / 220 / 2

Outcome results

Primary

Survival of Implant System (Kaplan Meier)

The primary endpoint is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method. Due to early study termination, the survival of the implant was analyzed at 3 years.

Time frame: 3 years

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
ASHCOM Shoulder System Subjects - Uncemented Humeral StemSurvival of Implant System (Kaplan Meier)21 Participants
ASHCOM Shoulder System Subjects - Fracture Humeral StemSurvival of Implant System (Kaplan Meier)2 Participants
Secondary

EQ-5D-5L Score

The EQ-5D-5L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes 5 questions referring to mobility, self-care, daily activities, pain/discomfort and anxiety/depression. Each question can be answered in five ways, indicating no, slight, moderate, severe problems or inability to complete the task. In the derived EQ-5D-5L score, the highest score is 1 and the lowest score is -0.573. It included the Health State, which is a self-reported assessment about the patient's health on that day at a VAS from 0 to 100 with 100 being the best health one can imagine and 0 the worst.

Time frame: Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative

Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit and for one patient the score was not collected at the 3-6 months and 1 year follow-up visit.

ArmMeasureGroupValue (MEAN)Dispersion
ASHCOM Shoulder System Subjects - Uncemented Humeral StemEQ-5D-5L Score3-6 Months0.79 score on a scaleStandard Deviation 0.11
ASHCOM Shoulder System Subjects - Uncemented Humeral StemEQ-5D-5L Score2 Year0.99 score on a scaleStandard Deviation 0.05
ASHCOM Shoulder System Subjects - Uncemented Humeral StemEQ-5D-5L Score1 Year0.97 score on a scaleStandard Deviation 0.08
ASHCOM Shoulder System Subjects - Uncemented Humeral StemEQ-5D-5L Score3 Year1.0 score on a scaleStandard Deviation 0.01
ASHCOM Shoulder System Subjects - Uncemented Humeral StemEQ-5D-5L ScorePreop0.22 score on a scaleStandard Deviation 0.16
ASHCOM Shoulder System Subjects - Fracture Humeral StemEQ-5D-5L Score3 Year0.97 score on a scaleStandard Deviation 0.04
ASHCOM Shoulder System Subjects - Fracture Humeral StemEQ-5D-5L ScorePreop0.06 score on a scaleStandard Deviation 0.07
ASHCOM Shoulder System Subjects - Fracture Humeral StemEQ-5D-5L Score3-6 Months0.56 score on a scaleStandard Deviation 0.15
ASHCOM Shoulder System Subjects - Fracture Humeral StemEQ-5D-5L Score1 Year0.67 score on a scaleStandard Deviation 0.17
ASHCOM Shoulder System Subjects - Fracture Humeral StemEQ-5D-5L Score2 Year0.88 score on a scaleStandard Deviation 0
Comparison: The small sample size of arm ASHCOM Shoulder System subjects - Fracture humeral stem of 2 cases is too low for a statistical analysis.p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary

Oxford Shoulder Score (OSS)

The Oxford Shoulder Score (OSS) is a patient-reported outcome questionnaire that was developed to specifically assess the patient's perspective of outcome following total shoulder arthroplasty. The OSS consists of twelve questions covering function and pain associated with the shoulder. To calculate the total score, each question is scored from 0 (worst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible and a minimum of 0, representing the worst possible. The outcome score can be categorized as: Satisfactory Joint Function: 40 - 48, Moderate-Mild Arthritis: 30 - 39, Moderate-Severe Arthritis: 20 - 29, Severe Arthritis: 0 - 19.

Time frame: Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative

Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit and for one patient the score was not collected at the 2 years follow-up.

ArmMeasureGroupValue (MEAN)Dispersion
ASHCOM Shoulder System Subjects - Uncemented Humeral StemOxford Shoulder Score (OSS)3-6 Month41.81 score on a scaleStandard Deviation 3.97
ASHCOM Shoulder System Subjects - Uncemented Humeral StemOxford Shoulder Score (OSS)2 Year47.8 score on a scaleStandard Deviation 0.52
ASHCOM Shoulder System Subjects - Uncemented Humeral StemOxford Shoulder Score (OSS)1 Year47.62 score on a scaleStandard Deviation 0.92
ASHCOM Shoulder System Subjects - Uncemented Humeral StemOxford Shoulder Score (OSS)3 Year48.0 score on a scaleStandard Deviation 0
ASHCOM Shoulder System Subjects - Uncemented Humeral StemOxford Shoulder Score (OSS)Preop6.27 score on a scaleStandard Deviation 3.56
ASHCOM Shoulder System Subjects - Fracture Humeral StemOxford Shoulder Score (OSS)3 Year47.5 score on a scaleStandard Deviation 0.71
ASHCOM Shoulder System Subjects - Fracture Humeral StemOxford Shoulder Score (OSS)Preop5.5 score on a scaleStandard Deviation 7.78
ASHCOM Shoulder System Subjects - Fracture Humeral StemOxford Shoulder Score (OSS)3-6 Month32.5 score on a scaleStandard Deviation 0.71
ASHCOM Shoulder System Subjects - Fracture Humeral StemOxford Shoulder Score (OSS)1 Year45.5 score on a scaleStandard Deviation 0.71
ASHCOM Shoulder System Subjects - Fracture Humeral StemOxford Shoulder Score (OSS)2 Year48.0 score on a scaleStandard Deviation 0
Comparison: The small sample size of arm ASHCOM Shoulder System subjects - Fracture humeral stem of 2 cases is too low for a statistical analysis.p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary

Radiographic Parameters

Radiographic parameters: X-rays have been evaluated for radiolucency, osteolysis, atrophy, hypertrophy, osteophytes (glenoid), component migration (humeral stem subsidence / glenoid component migration), heterotopic ossification and scapular notching

Time frame: 2 years post-operative

Population: ASHCOM Shoulder System subjects - Uncemented humeral stem: The number analyzed at 2 years is 21, as one patient passed away prior to the 3-6 month visit.

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
ASHCOM Shoulder System Subjects - Uncemented Humeral StemRadiographic ParametersAny radiographic findings - Yes:0 Participants
ASHCOM Shoulder System Subjects - Uncemented Humeral StemRadiographic ParametersAny radiographic findings - No:21 Participants
ASHCOM Shoulder System Subjects - Fracture Humeral StemRadiographic ParametersAny radiographic findings - Yes:0 Participants
ASHCOM Shoulder System Subjects - Fracture Humeral StemRadiographic ParametersAny radiographic findings - No:2 Participants
Secondary

Subjective Shoulder Value (SSV)

The Subjective Shoulder Value (SSV) is a single point, subjective estimate of a patient's condition. The patient is asked to rate the functionality of their operated shoulder on a scale of 0% - 100% of normal.

Time frame: Pre-operative (baseline), 3-6 months, 1 year, 2 and 3 years post-operative

Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit. For one patient the score was not collected at the 3-6 months follow-up visit and for two patients at the 1 year follow-up visit.

ArmMeasureGroupValue (MEAN)Dispersion
ASHCOM Shoulder System Subjects - Uncemented Humeral StemSubjective Shoulder Value (SSV)3-6 Months76.5 percentage of normalStandard Deviation 9.47
ASHCOM Shoulder System Subjects - Uncemented Humeral StemSubjective Shoulder Value (SSV)2 Year94.74 percentage of normalStandard Deviation 7.35
ASHCOM Shoulder System Subjects - Uncemented Humeral StemSubjective Shoulder Value (SSV)1 Year89.74 percentage of normalStandard Deviation 9.64
ASHCOM Shoulder System Subjects - Uncemented Humeral StemSubjective Shoulder Value (SSV)3 Year96.19 percentage of normalStandard Deviation 5.46
ASHCOM Shoulder System Subjects - Uncemented Humeral StemSubjective Shoulder Value (SSV)Preop25.0 percentage of normalStandard Deviation 14.72
ASHCOM Shoulder System Subjects - Fracture Humeral StemSubjective Shoulder Value (SSV)3 Year97.5 percentage of normalStandard Deviation 3.54
ASHCOM Shoulder System Subjects - Fracture Humeral StemSubjective Shoulder Value (SSV)Preop10.0 percentage of normalStandard Deviation 14.14
ASHCOM Shoulder System Subjects - Fracture Humeral StemSubjective Shoulder Value (SSV)3-6 Months62.5 percentage of normalStandard Deviation 3.54
ASHCOM Shoulder System Subjects - Fracture Humeral StemSubjective Shoulder Value (SSV)1 Year77.5 percentage of normalStandard Deviation 3.54
ASHCOM Shoulder System Subjects - Fracture Humeral StemSubjective Shoulder Value (SSV)2 Year90.0 percentage of normalStandard Deviation 0
Comparison: The small sample size of arm ASHCOM Shoulder System subjects - Fracture humeral stem of 2 cases is too low for a statistical analysis.p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary

The Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)

The secondary endpoint of this study is defined by the performance and clinical benefits of the ASHCOM Shoulder System at 5 years, which is assessed by the Constant and Murley score. Due to early study termination, the Constant and Murley Score was assessed at 2 years. The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points. The minimum score is 0 points (worst outcome), the maximum score possible is 100 points (best outcome).

Time frame: Pre-operative (baseline), 1 year, 2 years post-operative

Population: The number analyzed in one or more rows differs from overall number analyzed, as one patient passed away prior to the 3-6 month visit and for one patient the score was not collected at the 2 years follow-up.

ArmMeasureGroupValue (MEAN)Dispersion
ASHCOM Shoulder System Subjects - Uncemented Humeral StemThe Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)Preop7.91 score on a scaleStandard Deviation 8.18
ASHCOM Shoulder System Subjects - Uncemented Humeral StemThe Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)1 year74.0 score on a scaleStandard Deviation 12.55
ASHCOM Shoulder System Subjects - Uncemented Humeral StemThe Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)2 years82.95 score on a scaleStandard Deviation 8.65
ASHCOM Shoulder System Subjects - Fracture Humeral StemThe Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)Preop5.0 score on a scaleStandard Deviation 7.07
ASHCOM Shoulder System Subjects - Fracture Humeral StemThe Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)1 year55.0 score on a scaleStandard Deviation 4.24
ASHCOM Shoulder System Subjects - Fracture Humeral StemThe Performance and Clinical Benefits of the ASHCOM Shoulder System - Constant Murley Shoulder Score (CM)2 years70.5 score on a scaleStandard Deviation 9.19
Comparison: The small sample size of arm ASHCOM Shoulder System subjects - Fracture humeral stem of 2 cases is too low for a statistical analysis.p-value: <0.0001Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026